Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

NCT05180097 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

84

Enrollment

NETWORK

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: Gemcitabine
DRUG: Dexamethasone
DRUG: Cisplatin
DRUG: Brentuximab vedotin
DRUG: Pembrolizumab

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]
[object Object]
[object Object]